
Verdiva Bio presents preclinical data on obesity treatments
Verdiva Bio has announced new preclinical data for VRB-103, a once-weekly oral amylin receptor-selective amylin analog, and VRB-104, a unimolecular amylin and GLP-1 receptor dual agonist. The data were presented in poster sessions at the American Diabetes Association (ADA), taking place 5-8 June in New Orleans, Louisiana,… Read More














